1c1u: Difference between revisions

No edit summary
No edit summary
Line 4: Line 4:
|PDB= 1c1u |SIZE=350|CAPTION= <scene name='initialview01'>1c1u</scene>, resolution 1.75&Aring;
|PDB= 1c1u |SIZE=350|CAPTION= <scene name='initialview01'>1c1u</scene>, resolution 1.75&Aring;
|SITE=  
|SITE=  
|LIGAND= <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene> and <scene name='pdbligand=BAI:(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE'>BAI</scene>
|LIGAND= <scene name='pdbligand=BAI:(5-AMIDINO-2-BENZIMIDAZOLYL)(2-BENZIMIDAZOLYL)METHANE'>BAI</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=TYS:SULFONATED+TYROSINE'>TYS</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>
|ACTIVITY= [http://en.wikipedia.org/wiki/Thrombin Thrombin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.5 3.4.21.5]  
|ACTIVITY= <span class='plainlinks'>[http://en.wikipedia.org/wiki/Thrombin Thrombin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.5 3.4.21.5] </span>
|GENE=  
|GENE=  
|DOMAIN=
|RELATEDENTRY=[[1c2d|1C2D]], [[1c2f|1C2F]], [[1c2g|1C2G]], [[1c2h|1C2H]], [[1c2i|1C2I]], [[1c2l|1C2L]], [[1c2m|1C2M]], [[1c1n|1C1N]], [[1c1o|1C1O]], [[1c1p|1C1P]], [[1c1q|1C1Q]], [[1c1r|1C1R]], [[1c1s|1C1S]], [[1c1t|1C1T]], [[1c2e|1C2E]], [[1c1v|1C1V]], [[1c1w|1C1W]], [[1c2j|1C2J]]
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1c1u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1c1u OCA], [http://www.ebi.ac.uk/pdbsum/1c1u PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1c1u RCSB]</span>
}}
}}


Line 14: Line 17:
==Overview==
==Overview==
Many serine proteases are targets for therapeutic intervention because they often play key roles in disease. Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues. By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.
Many serine proteases are targets for therapeutic intervention because they often play key roles in disease. Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues. By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.
==Disease==
Known diseases associated with this structure: Dysprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hyperprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]], Hypoprothrombinemia OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176930 176930]]


==About this Structure==
==About this Structure==
Line 28: Line 28:
[[Category: Katz, B A.]]
[[Category: Katz, B A.]]
[[Category: Luong, C.]]
[[Category: Luong, C.]]
[[Category: BAI]]
[[Category: NA]]
[[Category: ZN]]
[[Category: ph dependence]]
[[Category: ph dependence]]
[[Category: serine protease/inhibitor]]
[[Category: serine protease/inhibitor]]
Line 36: Line 33:
[[Category: zn(ii)-mediated serine protease inhibitor]]
[[Category: zn(ii)-mediated serine protease inhibitor]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 10:18:43 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 19:12:48 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA